Global tuberculosis drug development pipeline: the need and the reality.
about
What research is needed to stop TB? Introducing the TB Research MovementCombating Tuberculosis Infection: A Forbidding ChallengeEffects of Fluroquinolones in Newly Diagnosed, Sputum-Positive Tuberculosis Therapy: A Systematic Review and Network Meta-AnalysisDelamanid expanded access novel treatment of drug resistant tuberculosisMycobacterium tuberculosis: success through dormancyTuberculosis drug discovery in the post-post-genomic eraRising to the challenge: new therapies for tuberculosisRedox homeostasis in mycobacteria: the key to tuberculosis control?Reverse translation in tuberculosis: neutrophils provide clues for understanding development of active diseaseStructural and functional studies of mycobacterial IspD enzymesStructural Basis of Mycobacterial Inhibition by Cyclomarin ALocal microbiologies of tuberculosis: insights from the Republic of GeorgiaProbing the interaction of the diarylquinoline TMC207 with its target mycobacterial ATP synthaseWild-type phosphoribosylpyrophosphate synthase (PRS) from Mycobacterium tuberculosis: a bacterial class II PRS?In vitro and in vivo activities of ruthenium(II) phosphine/diimine/picolinate complexes (SCAR) against Mycobacterium tuberculosisLooking back to the future: predicting in vivo efficacy of small molecules versus Mycobacterium tuberculosisBactericidal activity of an imidazo[1, 2-a]pyridine using a mouse M. tuberculosis infection modelConfinement-Induced Drug-Tolerance in Mycobacteria Mediated by an Efflux MechanismEvolution of Extensively Drug-Resistant Tuberculosis over Four Decades: Whole Genome Sequencing and Dating Analysis of Mycobacterium tuberculosis Isolates from KwaZulu-NatalPropargyl-Linked Antifolates Are Potent Inhibitors of Drug-Sensitive and Drug-Resistant Mycobacterium tuberculosisRecent advances in tuberculosis: New drugs and treatment regimens.Multidrug-Resistant TB: Implementing the Right to Health through the Right to Enjoy the Benefits of Scientific Progress.EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa.PCR to detect Mycobacterium tuberculosis in respiratory tract samples: evaluation of clinical data.Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for actionGenomic analysis of globally diverse Mycobacterium tuberculosis strains provides insights into the emergence and spread of multidrug resistance.Rational Design of Selective and Bioactive Inhibitors of the Mycobacterium tuberculosis Proteasome.Antitubercular therapy in patients with cirrhosis: challenges and optionsChallenges of antibacterial discoveryExploring serological classification tree model of active pulmonary tuberculosis by magnetic beads pretreatment and MALDI-TOF MS analysis.Protein-protein interaction networks suggest different targets have different propensities for triggering drug resistance.Current approaches to tuberculosis in the United States.Priorities for tuberculosis research: a systematic review.Enabling policy planning and innovation management through patent information and co-authorship network analyses: a study of tuberculosis in Brazil.Assay development for identifying inhibitors of the mycobacterial FadD32 activity.21st century natural product research and drug development and traditional medicinesThe challenge of new drug discovery for tuberculosis.Synthesis of glycoconjugate fragments of mycobacterial phosphatidylinositol mannosides and lipomannan.A multi-arm multi-stage clinical trial design for binary outcomes with application to tuberculosisDouble click reaction for the acquisition of a highly potent and selective mPTPB inhibitor
P2860
Q21563033-56249132-E271-484B-8769-FB10DDD6EEC2Q26750683-E6D2C42A-DBCB-47E7-8A8C-9DEE7698B86CQ26775757-BD62B3D9-825E-4BB8-B3C5-42214D58AD53Q26775858-DA193847-BAF6-406A-9966-EB2ACC620DA5Q26852023-27A44B1E-B301-4C45-B3FA-C9C7CAC93774Q26864729-283AA28A-2D80-4B28-81CD-C2C2CDAA2948Q27011672-5E4B2E49-0E0A-462A-85B0-53F536DA5C6DQ27012879-2643B10D-33BA-45A4-8E45-5623785EB3D5Q27027976-8FC19AAD-6FCB-4E27-91F0-DB108BDA4858Q27667712-5F1A2959-816C-4368-8E37-35FB6BB25CEBQ27679912-6D0EBE23-BAAC-4F41-8B89-51B78C1E6F1AQ28302818-8DDC448C-8D05-45F3-B6B9-34CA8A5FFFB4Q28476612-73C7A923-AE40-4E6D-BDC5-ED437AC72EAAQ28480557-A28BE626-E355-440D-A29E-354E3362F1CFQ28533382-413EED1B-9373-4974-8F62-5C43C0B5BF59Q28538272-DCA7D9C6-81D3-4397-8C35-4E502C3F99C5Q28539383-65AD5171-D0C5-4988-BE35-113C869413AAQ28547410-03D122F8-B224-4100-841D-6D1D0D74050EQ28548604-EB62AC4D-DCF1-42FC-98A0-779C7F146A89Q28553792-824F486E-0A01-450E-B9DF-87D114BEBAFFQ30360811-6ADF905B-4A66-4A4D-A751-DB3066520AD4Q30380955-2AAC8039-C7FE-4FED-AC8E-6E8A1B737B7EQ30393945-2F096A1A-8855-450F-B1E8-58D3E81F157CQ30672984-0436E5F8-1699-4FDF-B34A-F3BFC6DAE690Q33576909-864F578B-208E-4384-9154-8D9A57DCCE3EQ33595994-9D2D5FC5-A33C-42A9-B8BE-BF6E61ABFEAEQ33620526-E51D301C-9DE7-4333-94C8-FC8C0A48B052Q33626827-DF91A166-EC8E-43C1-80BC-CE3B1B572537Q33793074-B931E2D1-C0FF-4B56-BC53-4ABAB1AD0DACQ33930852-4AC11CF5-2C2B-42DE-B24B-9D7844BC1145Q34237349-31A49AF0-6477-462B-B709-58914D6945C6Q34279727-7CFCDD48-C9B8-47FC-B398-C9DFB800A20FQ34351616-397B3617-F1FB-4C91-B921-D9E94FDF60F3Q34440960-1F64C108-6966-46F6-B9E3-41E9B5FDFCCAQ34567891-F0E843FE-BF20-48BC-86A7-DD2F6CCA600DQ34602021-E838EFAF-613D-451F-8821-24E22C2C4F88Q34660424-2E7148DA-BF02-47ED-832E-2B528CEAD53BQ34811886-7B3F64BD-FB1D-4FC1-B621-0119E15550E4Q35042658-090F5AB8-A678-4A44-A366-2A2E6E1F4520Q35052636-8A039E4D-308F-4716-96B2-3216896B8F71
P2860
Global tuberculosis drug development pipeline: the need and the reality.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 18 May 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Global tuberculosis drug development pipeline: the need and the reality.
@en
Global tuberculosis drug development pipeline: the need and the reality.
@nl
type
label
Global tuberculosis drug development pipeline: the need and the reality.
@en
Global tuberculosis drug development pipeline: the need and the reality.
@nl
prefLabel
Global tuberculosis drug development pipeline: the need and the reality.
@en
Global tuberculosis drug development pipeline: the need and the reality.
@nl
P2093
P1433
P1476
Global tuberculosis drug development pipeline: the need and the reality
@en
P2093
Christian Lienhardt
Xiexiu Wang
Zhenkun Ma
P304
P356
10.1016/S0140-6736(10)60359-9
P407
P577
2010-05-18T00:00:00Z